Hikma Pharmaceuticals Plc (HIK) Rating Reiterated by Peel Hunt

Peel Hunt reaffirmed their hold rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a research note issued to investors on Wednesday, StockTargetPrices.com reports. They currently have a GBX 1,390 ($18.28) price objective on the stock.

Several other research analysts also recently commented on HIK. Jefferies Group LLC reissued a hold rating and issued a GBX 1,045 ($13.74) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday, November 9th. dropped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,060 ($13.94) to GBX 865 ($11.38) and set a reduce rating for the company in a research report on Friday, November 10th. J P Morgan Chase & Co dropped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,250 ($16.44) to GBX 1,000 ($13.15) and set a neutral rating for the company in a research report on Friday, November 10th. Stifel Nicolaus dropped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,320 ($17.36) to GBX 1,000 ($13.15) and set a hold rating for the company in a research report on Thursday, November 9th. Finally, Numis Securities Ltd restated an add rating and issued a GBX 1,560 ($20.52) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. Hikma Pharmaceuticals Plc has a consensus rating of Hold and an average price target of GBX 1,321.91 ($17.39).

Hikma Pharmaceuticals Plc (HIK) opened at GBX 1,041 ($13.69) on Wednesday. Hikma Pharmaceuticals Plc has a 1-year low of GBX 906.50 ($11.92) and a 1-year high of GBX 2,346 ($30.86).

COPYRIGHT VIOLATION NOTICE: “Hikma Pharmaceuticals Plc (HIK) Rating Reiterated by Peel Hunt” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://sportsperspectives.com/2017/11/19/hikma-pharmaceuticals-plc-hik-rating-reiterated-by-peel-hunt.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Stock Target Prices

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply